Alyson Harvey is a researcher developing replacement and reprogramming-based aging therapeutics. She completed her undergraduate degree in Chemical and Physical Biology at Harvard in 2025, where her thesis in David Sinclair's laboratory investigated epigenetic reprogramming as a novel therapeutic for motor neuron disease. She previously worked in George Church's laboratory, where she developed and evaluated cell fusion and transcriptomic rejuvenation protocols directed toward cellular age reversal and de-extinction applications. Her research has been awarded fellowships from Harvard's Program for Research in Science and Engineering (PRISE), Harvard College Research Program (HCRP), the Salata Institute, and the TIME Initiative.